- Home
- DQ vs MLYS Comparison
DQ vs MLYS Comparison
Compare DQ & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DQ
- MLYS
- Stock Information
- Founded
- DQ 2006
- MLYS 2019
- Country
- DQ China
- MLYS United States
- Employees
- DQ N/A
- MLYS N/A
- Industry
- DQ Semiconductors
- MLYS Biotechnology: Pharmaceutical Preparations
- Sector
- DQ Technology
- MLYS Health Care
- Exchange
- DQ Nasdaq
- MLYS Nasdaq
- Market Cap
- DQ 970.3M
- MLYS 1.0B
- IPO Year
- DQ 2010
- MLYS 2023
- Fundamental
- Price
- DQ $20.02
- MLYS $14.80
- Analyst Decision
- DQ Buy
- MLYS Strong Buy
- Analyst Count
- DQ 6
- MLYS 4
- Target Price
- DQ $23.91
- MLYS $27.00
- AVG Volume (30 Days)
- DQ 1.3M
- MLYS 922.1K
- Earning Date
- DQ 08-25-2025
- MLYS 08-12-2025
- Dividend Yield
- DQ N/A
- MLYS N/A
- EPS Growth
- DQ N/A
- MLYS N/A
- EPS
- DQ N/A
- MLYS N/A
- Revenue
- DQ $737,683,000.00
- MLYS N/A
- Revenue This Year
- DQ N/A
- MLYS N/A
- Revenue Next Year
- DQ $93.91
- MLYS N/A
- P/E Ratio
- DQ N/A
- MLYS N/A
- Revenue Growth
- DQ N/A
- MLYS N/A
- 52 Week Low
- DQ $12.41
- MLYS $8.24
- 52 Week High
- DQ $30.85
- MLYS $18.38
- Technical
- Relative Strength Index (RSI)
- DQ 72.79
- MLYS 53.41
- Support Level
- DQ $18.12
- MLYS $13.44
- Resistance Level
- DQ $21.00
- MLYS $14.70
- Average True Range (ATR)
- DQ 0.97
- MLYS 0.67
- MACD
- DQ 0.53
- MLYS 0.12
- Stochastic Oscillator
- DQ 86.65
- MLYS 99.44
About DQ DAQO New Energy Corp.
Daqo New Energy Corp is a polysilicon manufacturer based in China. The company manufactures and sells high-purity polysilicon to manufacturers who use it to make ingots, cells, and modules for solar power solutions. The polysilicon is packaged to meet crucible stacking, pulling, and solidification needs. All of the company's revenues come from the People's Republic of China.
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.